Lercanidipine hydrochloride
Brand names: Zanidip
Lercanidipine is a dihydropyridine calcium-channel blocker used in the treatment of essential hypertension.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It selectively inhibits L-type calcium channels in vascular smooth muscle, producing arterial vasodilatation that lowers peripheral vascular resistance and blood pressure.
Prescribing in practice
- Vasodilatory adverse effects such as ankle oedema, flushing and headache are common and may be dose-limiting.
- It is contraindicated in significant hepatic or severe renal impairment, in unstable angina, in untreated heart failure and within a short period after myocardial infarction, and grapefruit juice should be avoided as it increases drug exposure.
- It is best taken before food, as taking it with a high-fat meal can substantially increase absorption.
Monitoring
Monitor blood pressure for response and review the patient for ankle oedema and other vasodilatory effects.
Counselling the patient
- Take the medicine before food and avoid grapefruit juice.
- Ankle swelling, flushing or headache may occur, especially when starting treatment.
- Keep taking it regularly, as it controls rather than cures high blood pressure.
Evidence & guidelines
Dihydropyridine calcium-channel blockers such as lercanidipine are recommended for hypertension in NICE guidance, with well-established efficacy in lowering blood pressure.
Reference: NICE NG136; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines